Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, combined with endocrine therapy (ET), are becoming the standard-of-care for hormone receptor–positive/human epidermal growth factor receptor 2‒negative metastatic breast cancer, further mechanistic insights are needed to m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhou, Turner, Nicholas C., Loi, Sherene, André, Fabrice, Martin, Miguel, Diéras, Véronique, Gelmon, Karen A., Harbeck, Nadia, Zhang, Cathy, Cao, Joan Q., Yan, Zhengming, Lu, Dongrui R., Wei, Ping, VanArsdale, Todd L., Rejto, Paul A., Huang, Xin, Rugo, Hope S., Loibl, Sibylle, Cristofanilli, Massimo, Finn, Richard S., Liu, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381541/
https://www.ncbi.nlm.nih.gov/pubmed/35974168
http://dx.doi.org/10.1038/s41698-022-00297-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381541/
https://www.ncbi.nlm.nih.gov/pubmed/35974168
http://dx.doi.org/10.1038/s41698-022-00297-1

Ejemplares similares